10,7 millionen quartals - verlust - das vorhandene geld reicht nur noch bis ins 4. Quartal dieses jahr
Research and
development expense
$ 6,025
General and
administrative expense
$ 5,090
was laeuft
We have also entered into a Cooperative Research and Development Agreement, or CRADA, with the National
Cancer Institute, or NCI, part of the National Institutes of Health, to conduct a Phase 2/3 randomized, controlled clinical
trial testing the addition of uproleselan to a standard chemotherapy regimen. Enrollment of 267 patients in the Phase 2
portion was completed in December 2021. There will be a planned interim analysis that will evaluate event-free survival
and whether the pre-specified threshold for continuing to Phase 3 has been met.
In May 2023, the FDA agreed to our initial Pediatric Study Plan, and in October 2023, the European Medicines
Agency agreed to our Pediatric Investigational Plan. As part of these pediatric plans, an NCI-sponsored Phase 1/2
Enrollment in the Phase 1 trial is expected to be up to 18 patients. The first patient was enrolled in October 2023.
we filed an IND for GMI-1687 as a potential treatment for vaso-occlusive event (VOE),
a common complication of sickle cell disease, and in December 2023, we completed
enrollment of 40 subjects in a Phase 1a trial of GMI-1687 in healthy adult volunteers.
We are advancing other preclinical-stage programs, including small-molecule
glycomimetic compounds that inhibit the protein galectin-3
wie schauts mit den dollars aus
Since inception, we have incurred significant operating losses.
We had an accumulated deficit of $ 467.2 million as of
March 31, 2024 and we expect to continue to incur operating losses over at least the next several years. Our net losses may
fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical trials and our
expenditures on other research and development activities.
To fund further operations,
we will need to preserve our current
cash resources and
raise additional
capital.
we believe that our existing
cash and cash equivalents will be sufficient
to fund our operations through the fourth quarter of 2024
https://ir.glycomimetics.com/static-files/f45ff65d-e840-4e65…
m.e. wird noch eine menge geld benoetigt bis
ev. etwas "zaehlbares" bei rauskommt
oder auch wie fitsch 11 meinte : ......dauert noch Jahre